Cumberland Pharmaceuticals
CPIX
23 hedge funds and large institutions have $3.18M invested in Cumberland Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 2 closing their positions.
3,600% more call options, than puts
Call options by funds: $37K | Put options by funds: $1K
0% more funds holding
Funds holding: 23 → 23 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0.61% less ownership
Funds ownership: 15.25% → 14.64% (-0.61%)
13% less capital invested
Capital invested by funds: $3.63M → $3.18M (-$456K)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cresset Asset Management
Chicago,
Illinois
|
+$14.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$7.98K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$6.64K |
| 4 |
IC
Innealta Capital
Austin,
Texas
|
+$1.49K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.35K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
-$84.1K |
| 2 |
Two Sigma Advisers
New York
|
-$38.6K |
| 3 |
Two Sigma Investments
New York
|
-$20.6K |
| 4 |
Morgan Stanley
New York
|
-$13.5K |
| 5 |
Renaissance Technologies
New York
|
-$7.08K |
CPIX Hedge Fund Activity: Q2 2024 in Review
23 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Cumberland Pharmaceuticals (CPIX) for Q2 2024, worth a combined $3.18M — down 13% from $3.63M a quarter earlier.
Fund positioning in CPIX was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 6 trimmed.
The largest buyer was Cresset Asset Management, adding an estimated $14.2K. The largest seller was Dimensional Fund Advisors, cutting an estimated $84.1K.
- 23 institutional investors held Cumberland Pharmaceuticals (CPIX) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $3.18M of Cumberland Pharmaceuticals stock for Q2 2024, down 13% quarter-over-quarter.
- 2 funds opened new Cumberland Pharmaceuticals positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest Cumberland Pharmaceuticals buyer in Q2 2024 was Cresset Asset Management, an estimated $14.2K added.
- The largest Cumberland Pharmaceuticals seller in Q2 2024 was Dimensional Fund Advisors, an estimated $84.1K sold.
Based on aggregated 13F filings for Q2 2024.